The central hypothesis is that lutein supplementation will improve MPOD and cognition. Accordingly, the specific aims are to 1) to determine the process feasibility associated with participating in 4-month lutein supplementation trial; and 2) to investigate the scientific feasibility of 4-month daily lutein supplementation on biological markers of lutein status and cognitive function among persons with MS.

A two-group parallel design will be employed whereby participants will be randomly assigned to one of 2 groups. The supplementation doses 20mg/d (Group 1), and placebo (Group 2) will be consumed daily by the participant for a 4-month period. Pre-test and follow-up measures of lutein status and cognitive function will be assessed at baseline and at 4-month follow-up via laboratory visits.

Inclusion Criteria:

• 18-64.9 years
• Self-reported relapsing-remitting MS (RRMS) diagnosis
• Expanded Disability Status Scale (EDSS) score between 0-3.5
• Macular Pigment Optical Density at baseline (MPOD ≤0.35)
• Score ≤55 during the Symbol Digit Modalities Test (SDMT)
• 20/20 or corrected vision
• No presence of color blindness
• No history of age-related macular degeneration
• No history of epileptic seizures

Exclusion Criteria:

• Under 18 years or over 64.9 years
• MS diagnosis other than RRMS
• Pregnancy
• Uncorrected vision
• Presence of color blindness
• PDDS score of 7 or more
• Prior diagnosis of age-related macular degeneration
• History of epileptic seizures